Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CVS shares jump after 'strong start' to new year

(Sharecast News) - Full-year results from CVS Group were well received by the market on Tuesday as the veterinary services group announced a "strong start" to the new financial year, helped by its continued expansion strategy in Australia. The company, which flagged the headline figures for the 12 months to 30 June in a trading update in July, said it was looking forward to the conclusion of the "prolonged" veterinary market investigation by the Competition and Markets Authority, expected in mid-October.

"I am delighted to report on another successful year of growth across our group with improved UK operations and the establishment of a meaningful platform in Australia," said chief executive Richard Fairman.

"We have successfully navigated some significant challenges over the past twelve months, and we enter the new financial year with a strengthened group, which is well positioned for further success."

Group revenues were 5.4% higher at £673.2m during the period. Like-for-like sales rose by just 0.2%, but core veterinary practices LFL sales were 1% higher, with improved revenue and LFL growth seen in the fourth quarter.

Adjusted pre-tax profit was flat at £78.9m due to higher finance expenses and depreciation from continued acquisitions and capital investments.

Nevertheless, the company still raised its final dividend to 8.5p per share, up from 8.0p previously, "reflecting the board's confidence in the long-term outlook for the group".

CVS reiterated its guidance of like-for-like organic growth of between 4-8% over the medium term, saying that the positive momentum in underlying sales seen in the fourth quarter has continued into the new financial year. The company said it was expects to hit market expectations for FY26 adjusted EBITDA of £138.9m-143.2m.

Shares were up around 10% at 1,370p by 1134 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.